Skip to main content
Premium Trial:

Request an Annual Quote

EU Consortium Gets €14M to Personalize Treatment of Inflammatory Diseases

NEW YORK (GenomeWeb) – A new international consortium called SYSCID (A systems medicine approach to chronic inflammatory disease) has received €14.4 million ($15.3 million) to support a five-year research project with the goal of developing personalized medicine approaches for inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus.

Coordinated by Kiel University in Germany, the effort involves academic and industry partners from nine different countries.

Philip Rosenstiel, scientific coordinator of the SYSCID consortium, said in a statement that the effort will investigating a variety of biomarkers "from the epigenome to the microbiome," as well as tools like single-cell analysis. Using build data from previous and ongoing research activities like the International Human Epigenome Consortium, SYSCID hopes to better understand patient response and non-response to current treatment regimens.

"With many new targeted therapies coming to the market, we need the right therapy at the right time," Rosenstiel added.

The project will also seek to develop new therapeutic strategies that address root causes of disease, such as epigenetics, rather than just their immune effects and symptoms.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.